IPP Bureau
AstraZeneca’s Imfinzi cuts death risk by 32% in high-risk non-muscle-invasive bladder cancer
By IPP Bureau - October 22, 2025
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
AbbVie completes acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
By IPP Bureau - October 22, 2025
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
Enzalutamide leads to 40% lower risk of death in prostate cancer
By IPP Bureau - October 22, 2025
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Pfizer’s Braftovi+Mektovi shows sustained long-term survival in patients with advanced lung cancer
By IPP Bureau - October 22, 2025
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Merck breaks ground on $3 billion center of excellence for pharma manufacturing in Virginia
By IPP Bureau - October 22, 2025
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Bajaj Healthcare posts Q2 FY26 PAT at Rs. 11.10 Cr
By IPP Bureau - October 22, 2025
Bajaj Healthcare has reported total income of Rs. 149.56 crore during the period ended September 30, 2025
TTK Healthcare reports Q2 FY26 net profit at Rs. 20.38 Cr
By IPP Bureau - October 22, 2025
TTK Healthcare has reported total income of Rs. 222.58 crore during the period ended September 30, 2025
Qure.ai receives regulatory clearance for AI tool for early detection of TB in children below 3 years
By IPP Bureau - October 22, 2025
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
RPG Life Sciences posts Q2 FY26 PAT at Rs. 36.85 Cr
By IPP Bureau - October 22, 2025
RPG Life Sciences has reported total income of Rs. 186.22 crore during the period ended September 30, 2025
Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC
By IPP Bureau - October 22, 2025
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer
By IPP Bureau - October 22, 2025
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Lundbeck and Contera Pharma join forces to advance RNA therapies for neurological disorders
By IPP Bureau - October 22, 2025
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Roche presents positive phase III data for vamikibart in uveitic macular edema
By IPP Bureau - October 22, 2025
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
AbbVie's Rinvoq beats Humira in key arthritis trial
By IPP Bureau - October 22, 2025
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Cambrex to invest $120 million to expand API manufacturing in US
By IPP Bureau - October 22, 2025
Expanding US operations to address the increased demand for API development and manufacturing
